The role of hepatic lipids in hepatic insulin resistance and type 2 diabetes
Non-alcoholic fatty liver disease and its downstream sequelae, hepatic insulin resistance
and type 2 diabetes, are rapidly growing epidemics, which lead to increased morbidity and …
and type 2 diabetes, are rapidly growing epidemics, which lead to increased morbidity and …
Strategies, models and biomarkers in experimental non-alcoholic fatty liver disease research
J Willebrords, IVA Pereira, M Maes, SC Yanguas… - Progress in lipid …, 2015 - Elsevier
Non-alcoholic fatty liver disease encompasses a spectrum of liver diseases, including
simple steatosis, steatohepatitis, liver fibrosis and cirrhosis and hepatocellular carcinoma …
simple steatosis, steatohepatitis, liver fibrosis and cirrhosis and hepatocellular carcinoma …
PPARs and mitochondrial metabolism: from NAFLD to HCC
T Mello, M Materozzi, A Galli - PPAR research, 2016 - Wiley Online Library
Metabolic related diseases, such as type 2 diabetes, metabolic syndrome, and nonalcoholic
fatty liver disease (NAFLD), are widespread threats which bring about a significant burden of …
fatty liver disease (NAFLD), are widespread threats which bring about a significant burden of …
SHP-1 acts as a tumor suppressor in hepatocarcinogenesis and HCC progression
LZ Wen, K Ding, ZR Wang, CH Ding, SJ Lei, JP Liu… - Cancer research, 2018 - AACR
Abstract Src homology region 2 (SH2) domain–containing phosphatase 1 (SHP-1, also
known as PTPN6) is a nonreceptor protein tyrosine phosphatase that acts as a negative …
known as PTPN6) is a nonreceptor protein tyrosine phosphatase that acts as a negative …
[HTML][HTML] METTL14 benefits the mesenchymal stem cells in patients with steroid-associated osteonecrosis of the femoral head by regulating the m6A level of PTPN6
C Cheng, H Zhang, J Zheng, Y **, D Wang… - Aging (Albany NY …, 2021 - ncbi.nlm.nih.gov
Imbalanced osteogenic/adipogenic differentiation of bone marrow mesenchymal stem cells
(BMSCs) is considered the core pathological characteristic of steroid-associated …
(BMSCs) is considered the core pathological characteristic of steroid-associated …
Protein tyrosine phosphatases: molecular switches in metabolism and diabetes
EN Gurzov, WJ Stanley, TC Brodnicki… - Trends in Endocrinology & …, 2015 - cell.com
Protein tyrosine phosphatases (PTPs) are a large family of enzymes that generally oppose
the actions of protein tyrosine kinases (PTKs). Genetic polymorphisms for particular PTPs …
the actions of protein tyrosine kinases (PTKs). Genetic polymorphisms for particular PTPs …
The HNF1α-regulated lncRNA HNF1A-AS1 reverses the malignancy of hepatocellular carcinoma by enhancing the phosphatase activity of SHP-1
Background Our previous study has demonstrated that hepatocyte nuclear factor 1α
(HNF1α) exerts potent therapeutic effects on hepatocellular carcinoma (HCC). However, the …
(HNF1α) exerts potent therapeutic effects on hepatocellular carcinoma (HCC). However, the …
An HNF1α-regulated feedback circuit modulates hepatic fibrogenesis via the crosstalk between hepatocytes and hepatic stellate cells
H Qian, X Deng, ZW Huang, J Wei, CH Ding, RX Feng… - Cell research, 2015 - nature.com
Hepatocytes are critical for the maintenance of liver homeostasis, but its involvement in
hepatic fibrogenesis remains elusive. Hepatocyte nuclear factor 1α (HNF1α) is a liver …
hepatic fibrogenesis remains elusive. Hepatocyte nuclear factor 1α (HNF1α) is a liver …
Phloretin attenuates STAT-3 activity and overcomes sorafenib resistance targeting SHP-1–mediated inhibition of STAT3 and Akt/VEGFR2 pathway in hepatocellular …
S Saraswati, A Alhaider, AM Abdelgadir… - Cell Communication and …, 2019 - Springer
Background Hepatocellular carcinoma (HCC) is the most common primary liver malignancy.
Phloretin (PH) possesses anticancer, antitumor, and hepatoprotective effects, however, the …
Phloretin (PH) possesses anticancer, antitumor, and hepatoprotective effects, however, the …
The role of GLP1-RAs in direct modulation of lipid metabolism in hepatic tissue as determined using in vitro models of NAFLD
Glucagon-like peptide 1 receptor agonists (GLP-1RAs) have been shown to improve
glucose and lipid homeostasis, promote weight loss, and reduce cardiovascular risk factors …
glucose and lipid homeostasis, promote weight loss, and reduce cardiovascular risk factors …